China's State FDA Imposes New Regulatory Requirements On CMOs And Third-party Contracts
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - In a bid to prevent the export of counterfeit medicines, China is tightening its supervision of contract manufacturing organizations doing work for overseas drug makers. To that end, China's State FDA recently issued a notice on new rules governing cross-border contract manufacturing